<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364156</url>
  </required_header>
  <id_info>
    <org_study_id>801851</org_study_id>
    <secondary_id>P50CA084718</secondary_id>
    <nct_id>NCT00364156</nct_id>
  </id_info>
  <brief_title>Comparison of Standard Versus Extended Nicotine Patch Therapy for Smoking Cessation</brief_title>
  <official_title>Comparison of Standard Versus Extended Nicotine Patch Therapy for Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized double-blind, placebo-controlled will determine the relative efficacy of
      standard versus extended transdermal nicotine (TN) therapy for smoking cessation. After
      completing the eligibility screening, 600 treatment-seeking smokers will be randomized to
      receive either standard treatment (ST) with TN (21mg x 8 weeks, placebo x 16 weeks) or
      extended treatment (ET) with TN (21mg x 24 weeks). All participants will receive behavioral
      counseling. The primary outcome will be biochemically verified abstinence from smoking at the
      end of treatment (week 24). Secondary outcomes include abstinence at week 28 (4 weeks after
      treatment is discontinued), and time to failure. We hypothesize that ET will produce
      significantly higher quit rates than ST; however, the benefit of ET will last only so long as
      treatment is continued. Support for this hypothesis would indicate that maintenance therapy
      with TN should be considered.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please see brief summary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemically Verified 7-day Point Prevalence Abstinence</measure>
    <time_frame>End of Treatment (week 24)</time_frame>
    <description>To evaluate the efficacy of standard (8-week) vs. extended (24-week) transdermal nicotine therapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">568</enrollment>
  <condition>TOBACCO USE CESSATION</condition>
  <arm_group>
    <arm_group_label>Extended Patch Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this treatment arm receive 24 weeks of 21mg nicotine patch in addition to 8 smoking cessation counseling sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Patch Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive 8 weeks of 21mg nicotine patch followed by 16 weeks of placebo patch.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Patch Treatment</intervention_name>
    <description>8-weeks of nicotine patch + 16-weeks of placebo</description>
    <arm_group_label>Standard Patch Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>24-weeks of nicotine patch</intervention_name>
    <description>24-weeks of 21mg nicotine patch</description>
    <arm_group_label>Extended Patch Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females of descent between the ages of 18-65 who smokes at least 10
             cigarettes/day and are seeking smoking cessation treatment.

          2. Based on the medical history, physical and laboratory examination, premenopausal
             female subjects must consent to practice an effective form of contraception during
             study.

          3. Following orientation by the research staff, subjects must sign written informed
             consent for all study procedures.

        Exclusion Criteria:

          1. Women who are pregnant, planning a pregnancy, or lactating.

          2. Current medical problems for which TN is contraindicated including allergy to
             nicotine, uncontrolled hypertension, unstable angina, serious arrhythmia, heart attack
             or stroke within the past 6 months, liver and/or kidney failure in the last 6-months
             and current diabetes.

          3. Current treatment of cancer or diagnosed with cancer in the past 6 months

          4. Current DSM IV substance use disorders (dependence involving alcohol, cocaine,
             marijuana or stimulants, benzodiazepines).

          5. Current use of TN or other forms of NRT.

          6. Concomitant medications (e.g., monoamine oxidase inhibitors or benzodiazepines within
             past 14 days, antipsychotics, endogenous steroids, and antidepressants (including
             wellbutrin or bupropion).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caryn Lerman, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tobacco Use Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Patterson F, Kerrin K, Wileyto EP, Lerman C. Increase in anger symptoms after smoking cessation predicts relapse. Drug Alcohol Depend. 2008 May 1;95(1-2):173-6. doi: 10.1016/j.drugalcdep.2008.01.013. Epub 2008 Mar 6.</citation>
    <PMID>18328642</PMID>
  </results_reference>
  <results_reference>
    <citation>Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, Asch DA, Lerman C. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med. 2010 Feb 2;152(3):144-51. doi: 10.7326/0003-4819-152-3-201002020-00005.</citation>
    <PMID>20124230</PMID>
  </results_reference>
  <results_reference>
    <citation>Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav. 2009 Mar;92(1):6-11. doi: 10.1016/j.pbb.2008.10.016. Epub 2008 Oct 31.</citation>
    <PMID>19000709</PMID>
  </results_reference>
  <results_reference>
    <citation>Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, Benowitz N, Tyndale RF. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin Pharmacol Ther. 2010 May;87(5):553-7. doi: 10.1038/clpt.2010.3. Epub 2010 Mar 24.</citation>
    <PMID>20336063</PMID>
  </results_reference>
  <results_reference>
    <citation>Ray R, Mitra N, Baldwin D, Guo M, Patterson F, Heitjan DF, Jepson C, Wileyto EP, Wei J, Payne T, Ma JZ, Li MD, Lerman C. Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. Neuropsychopharmacology. 2010 May;35(6):1374-82. doi: 10.1038/npp.2010.7. Epub 2010 Feb 10.</citation>
    <PMID>20147892</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2006</study_first_submitted>
  <study_first_submitted_qc>August 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <results_first_submitted>October 6, 2010</results_first_submitted>
  <results_first_submitted_qc>October 6, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 2, 2010</results_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited using mass media advertising from the the Greater Philadelphia area from June 2004 to April 2008.</recruitment_details>
      <pre_assignment_details>Once participants were enrolled and were eligible at the medical screening visit they were randomized to receiving either 8 weeks of 21 mg nicotine patch or 6 months of 21 mg nicotine patch treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Extended Patch Treatment</title>
          <description>Participants in this treatment arm receive 24 weeks of 21 mg nicotine patch in addition to 8 smoking cessation counseling sessions.</description>
        </group>
        <group group_id="P2">
          <title>Standard Patch Treatment</title>
          <description>Participants receive 8 weeks of 21 mg nicotine patch followed by 16 weeks of placebo patch.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="282"/>
                <participants group_id="P2" count="286"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="205"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Extended Patch Treatment</title>
          <description>Participants in this treatment arm receive 24 weeks of 21 mg nicotine patch in addition to 8 smoking cessation counseling sessions.</description>
        </group>
        <group group_id="B2">
          <title>Standard Patch Treatment</title>
          <description>Participants receive 8 weeks of 21 mg nicotine patch followed by 16 weeks of placebo patch.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="282"/>
            <count group_id="B2" value="286"/>
            <count group_id="B3" value="568"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="281"/>
                    <measurement group_id="B2" value="286"/>
                    <measurement group_id="B3" value="567"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.8" spread="10.2"/>
                    <measurement group_id="B2" value="44.9" spread="10.4"/>
                    <measurement group_id="B3" value="44.8" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="254"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="282"/>
                    <measurement group_id="B2" value="286"/>
                    <measurement group_id="B3" value="568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biochemically Verified 7-day Point Prevalence Abstinence</title>
        <description>To evaluate the efficacy of standard (8-week) vs. extended (24-week) transdermal nicotine therapy.</description>
        <time_frame>End of Treatment (week 24)</time_frame>
        <population>Intention to Treat analysis (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Patch Treatment</title>
            <description>Participants in this treatment arm receive 24 weeks of 21 mg nicotine patch in addition to 8 smoking cessation counseling sessions.</description>
          </group>
          <group group_id="O2">
            <title>Standard Patch Treatment</title>
            <description>Participants receive 8 weeks of 21 mg nicotine patch followed by 16 weeks of placebo patch.</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemically Verified 7-day Point Prevalence Abstinence</title>
          <description>To evaluate the efficacy of standard (8-week) vs. extended (24-week) transdermal nicotine therapy.</description>
          <population>Intention to Treat analysis (ITT)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Extended Patch Treatment</title>
          <description>Participants in this treatment arm receive 24 weeks of 21 mg nicotine patch in addition to 8 smoking cessation counseling sessions.</description>
        </group>
        <group group_id="E2">
          <title>Standard Patch Treatment</title>
          <description>Participants receive 8 weeks of 21 mg nicotine patch followed by 16 weeks of placebo patch.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <description>10/4/2007: Participant disclosed that she had recently had a stroke shortly after her last visit to the center. She sought medical attention immediately and was advised by her physician to discontinue use of the nicotine patch.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>2 Participants had high BP readings &gt;200/110 during participating in the study. Both participants were encouraged to received medical help for uncontrolled hypertension, and discontinue nicotine patch treatment and only receive counseling.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure during Blood Draw</sub_title>
                <description>4/17/2006: Participant had a 30-40 sec seizure after their blood draw. Participant recovered on their own from the seizure. Participant was monitored &amp; their vitals were normal. Participants successfully completed rest of the session feeling normal</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agressive Thoughts</sub_title>
                <description>10/23/2007-During Session 2 of the study participant reported feeling distraught &amp; aggressive thoughts towards family members due to certain personal circumstances. Case discussed &amp; participant provided with mental health helpline &amp; other resources.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Caryn Lerman</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-746-7141</phone>
      <email>clerman@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

